Published in Eur J Clin Pharmacol on July 20, 2011
The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol (2016) 0.86
Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems. Drug Saf (2015) 0.81
The out-of-focus bias in drug surveillance. Eur J Clin Pharmacol (2012) 0.77
Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. Springerplus (2016) 0.75
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
Closing the gap in a generation: health equity through action on the social determinants of health. A report of the WHO Commission on Social Determinants of Health (CSDH) 2008. Community Dent Health (2009) 11.48
Partnerships with patients: the pros and cons of shared clinical decision-making. J Health Serv Res Policy (1997) 9.78
Achieving health equity: from root causes to fair outcomes. Lancet (2007) 9.36
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
The pharmaceutical industry--to whom is it accountable? N Engl J Med (2000) 7.43
Failing the public health--rofecoxib, Merck, and the FDA. N Engl J Med (2004) 7.06
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. J Gen Intern Med (2002) 4.79
Qualitative research and evidence based medicine. BMJ (1998) 4.49
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet (1986) 4.48
Lost in transmission--FDA drug information that never reaches clinicians. N Engl J Med (2009) 4.12
Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns (2000) 3.94
Narrative based medicine: why study narrative? BMJ (1999) 3.74
Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol (2003) 3.51
Involving users in the delivery and evaluation of mental health services: systematic review. BMJ (2002) 3.51
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
Patient-reported medication symptoms in primary care. Arch Intern Med (2005) 2.89
COX-2 inhibitors--lessons in drug safety. N Engl J Med (2005) 2.39
Are the millennium development goals on target? BMJ (2010) 2.35
Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol (2008) 2.24
Communicating with patients about harms and risks. PLoS Med (2005) 2.03
FDA to review "missing" drug company documents. BMJ (2005) 2.03
Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf (2006) 2.01
Moving from information transfer to information exchange in health and health care. Soc Sci Med (2003) 1.88
Patients and the public deserve big changes in evaluation of drugs. BMJ (2009) 1.88
Estimating disease prevalence using a population-based administrative healthcare database. Scand J Public Health (2007) 1.72
Self-treatment and its discussion in medical consultations: how is medical pluralism managed in practice? Soc Sci Med (2003) 1.66
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med (1997) 1.58
Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol (2007) 1.41
Lessons from a patient partnership intervention to prevent adverse drug events. Int J Qual Health Care (2004) 1.39
Action on the social determinants of health and health inequities goes global. Annu Rev Public Health (2011) 1.38
Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol (2000) 1.37
Pharmacovigilance in perspective. Drug Saf (1999) 1.36
The Neurontin legacy--marketing through misinformation and manipulation. N Engl J Med (2009) 1.34
Implementing participatory intervention and research in communities: lessons from the Kahnawake Schools Diabetes Prevention Project in Canada. Soc Sci Med (2003) 1.32
Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol (2002) 1.30
Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med (2001) 1.29
The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf (1998) 1.25
Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J (2003) 1.20
Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry (2008) 1.17
Frailty and chronic diseases in older adults. Clin Geriatr Med (2011) 1.10
What effects do patients feel from their antihypertensive tablets and how do they react to them? Qualitative analysis of interviews with patients. Fam Pract (2005) 1.07
Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf (2009) 1.07
The effect of decision aids on the agreement between women's and physicians' decisional conflict about hormone replacement therapy. Patient Educ Couns (2003) 1.05
Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf (2011) 1.04
Using expert patients' narratives as an educational resource. Patient Educ Couns (2005) 1.03
Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann Clin Psychiatry (2008) 1.02
Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study. J Clin Oncol (1990) 0.98
A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther (2011) 0.94
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. Am Heart J (1997) 0.94
Improving pharmacovigilance in Europe. BMJ (2010) 0.94
Zidovudine use in AIDS-free HIV-1-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr (1991) 0.91
Women's control and choice regarding HRT. Soc Sci Med (1999) 0.90
Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk. Eur J Clin Pharmacol (2009) 0.88
Prenatal diagnosis: choices women make about pursuing testing and acting on abnormal results. Clin Obstet Gynecol (1993) 0.87
Risk Management Plans: are they a tool for improving drug safety? Eur J Clin Pharmacol (2010) 0.87
The effect of patient self-completion agenda forms on prescribing and adherence in general practice: a randomized controlled trial. Fam Pract (2006) 0.84
Adherence to antibiotics prescribed in an accident and emergency department: the influence of consultation factors. Eur J Emerg Med (2001) 0.83
Quality of care in frail older people: the fragile balance between receiving and giving. BMJ (2011) 0.82
Modern methods of pharmacovigilance: detecting adverse effects of drugs. Clin Med (2009) 0.81
New rules will allow EU patients to report drug concerns directly. BMJ (2010) 0.80
Direct reporting of suspected adverse drug reactions by patients. J R Soc Med (2004) 0.79
Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Drug Saf (2009) 0.77
Today's FDA. N Engl J Med (2005) 0.76
FDA post-marketing safety decisions. J Clin Psychiatry (2006) 0.75
[Epidemiology of problems related to drugs and devices in nursing homes in various regions of Italy]. Assist Inferm Ric (2007) 0.75
'Going public' and 'watching sick people'--the clinic setting as a factor in the experiences of gay men participating in AIDS clinical trials. AIDS Care (1995) 0.75
Pharmacovigilance in Australia and New Zealand: towards 2000. Med J Aust (1999) 0.75
Power and dependence; social audit on the safety of medicines. Int J Risk Saf Med (1992) 0.75
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med (2014) 7.07
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Association of aspirin use with major bleeding in patients with and without diabetes. JAMA (2012) 4.94
Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (2009) 3.83
Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.78
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care (2003) 3.68
Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med (2009) 3.60
Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol (2012) 3.42
Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized controlled trial. JAMA (2009) 3.35
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89
Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med (2010) 2.88
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J (2007) 2.42
Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2004) 2.31
Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet (2007) 2.25
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol (2008) 2.17
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 2.09
Purging iron from the heart. Br J Haematol (2004) 2.07
Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med (2003) 2.05
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail (2010) 1.78
Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail (2003) 1.77
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood (2006) 1.76
Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care (2002) 1.68
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J (2009) 1.63
Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol (2008) 1.61
Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram. Circ Heart Fail (2012) 1.59
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol (2002) 1.58
Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med (2012) 1.56
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol (2006) 1.54
Sequential N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin Measurements During Albumin Replacement in Patients With Severe Sepsis or Septic Shock. Crit Care Med (2016) 1.53
Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail (2004) 1.53
Participation versus education: the GISSI story and beyond. Am Heart J (2004) 1.52
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J (2005) 1.46
Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk? Eur J Clin Pharmacol (2005) 1.42
Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study. PLoS One (2013) 1.41
[Determinants of late-onset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results]. Rev Esp Cardiol (2005) 1.41
Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care (2005) 1.36
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation (2011) 1.35
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 1.34
Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol (2005) 1.31
Quality of care and outcomes in type 2 diabetic patients: a comparison between general practice and diabetes clinics. Diabetes Care (2004) 1.31
Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS Genet (2006) 1.29
Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care (2014) 1.27
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Improving outcomes for children with cancer in low-income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer (2007) 1.22
Quality of diabetes care predicts the development of cardiovascular events: results of the QuED study. Nutr Metab Cardiovasc Dis (2006) 1.21
Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J (2011) 1.15
Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J (2010) 1.12
AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J (2007) 1.12
Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol (2002) 1.09
Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis (2007) 1.09
The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail (2007) 1.08
Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol (2007) 1.08
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail (2007) 1.07
Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med (2014) 1.06
Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail (2012) 1.06
Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost (2005) 1.05
Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) (2006) 1.04
Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J (2010) 1.04
Community participation eliminates yaws in Ecuador. Trop Med Int Health (2003) 1.03
Pattern of diagnostic and therapeutic care of childhood epilepsy in Alexandria, Egypt. Int J Qual Health Care (2002) 1.03
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med (2006) 1.03
Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur J Clin Pharmacol (2004) 1.02
Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail (2005) 1.01
APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis (2003) 1.01
Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol (2007) 1.01
Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study. J Gerontol A Biol Sci Med Sci (2012) 1.00
The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design. Am Heart J (2011) 0.99
Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care (2005) 0.98
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail (2006) 0.98
Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)-Prevenzione trial. Circulation (2007) 0.96
Educational inequalities in obesity, abdominal obesity, and metabolic syndrome in seven Latin American cities: the CARMELA Study. Eur J Cardiovasc Prev Rehabil (2011) 0.96
Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis (2012) 0.96